The generic versions will give patients and healthcare providers access to “affordable alternatives" to brand name formats, says Canadian drug manufacturer, Apotex ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

Novo Nordisk has flagged growing generic competition in markets including India as a potential drag on its international business in 2026, highlighting rising pressure on branded obesity and diabetes ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

The most significant addition to the Java language since Sun Microsystems rewrote the collections API for Java 5 is the introduction of Java records. Java records address two significant pain points ...

A generic version of Wegovy is not currently available in the United States due to patents held by the manufacturer, Novo Nordisk, that may remain in effect until 2041. When the U.S. patent for ...

Java is an object-oriented programming language. To create objects and meaningfully initialize them, a developer must use a Java constructor. Constructors are a critical part of software development ...

Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

Merck’s guidance for the year—anticipating sales between 20 billion euros and 21 billion euros, or -1% to 2% growth— “assumes no U.S. sales of Mavenclad from March 2026 amid generic competition.” ...

A revolution is coming in the U.S. generics marketplace, one that has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for ...